Literature DB >> 15896001

The receptor binding domain of apolipoprotein E is responsible for its antioxidant activity.

Thomas Pham1, Ahmer Kodvawala, David Y Hui.   

Abstract

Apolipoprotein E (apoE) is a 34-kDa lipid-associated protein present in plasma and in the central nervous system. Previous studies have demonstrated that apoE has multiple functions, including the ability to transport lipids, regulate cell homeostasis, and inhibit lipid oxidation. The lipid binding domain of apoE has been localized to the carboxyl-terminal domain, whereas a cluster of basic amino acid residues within the N-terminal domain is responsible for its receptor binding activity. This study was undertaken to identify the domain in apoE responsible for its antioxidant activity. Results showed that apoE inhibits Cu(2+)-induced LDL oxidation by delaying conjugated diene formation in a concentration-dependent manner. Reductive methylation of lysine residues or cyclohexanedione modification of arginine residues in apoE abolished its ability to inhibit LDL oxidation. Additional studies showed that a 22-kDa peptide containing the N-terminal domain of apoE3 was more effective than a similar peptide with the apoE4 sequence in inhibiting Cu(2+)-induced LDL oxidation. In contrast, the 10-kDa peptide that contains the C-terminal domain of apoE was ineffective. Inhibition of Cu(2+)-induced LDL oxidation can also be accomplished with a peptide containing either a single sequence or a tandem repeat sequence of the receptor binding domain (residues 141-155) of apoE. Taken together, these results localized the antioxidant domain of apoE to its receptor binding domain and the basic amino acids in this domain are important for its antioxidant activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15896001     DOI: 10.1021/bi0472696

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

Review 1.  The role of apolipoprotein E in Guillain-Barré syndrome and experimental autoimmune neuritis.

Authors:  Hong-liang Zhang; Jiang Wu; Jie Zhu
Journal:  J Biomed Biotechnol       Date:  2010-02-16

2.  Targeted In Situ Gene Correction of Dysfunctional APOE Alleles to Produce Atheroprotective Plasma ApoE3 Protein.

Authors:  Ioannis Papaioannou; J Paul Simons; James S Owen
Journal:  Cardiol Res Pract       Date:  2012-05-07       Impact factor: 1.866

3.  apoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL.

Authors:  Panagiotis Fotakis; Alexander Vezeridis; Ioannis Dafnis; Angeliki Chroni; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2014-04-28       Impact factor: 5.922

4.  Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall.

Authors:  Godfrey S Getz; Catherine A Reardon
Journal:  J Lipid Res       Date:  2008-11-18       Impact factor: 5.922

5.  Association of the apolipoprotein E 2 allele with concurrent occurrence of endometrial hyperplasia and endometrial carcinoma.

Authors:  Tatiana I Ivanova; Ludmila I Krikunova; Nikolay I Ryabchenko; Liana S Mkrtchyan; Vera A Khorokhorina; Lyubov E Salnikova
Journal:  Oxid Med Cell Longev       Date:  2015-02-09       Impact factor: 6.543

Review 6.  The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease.

Authors:  Carlota Recio; Francesco Maione; Asif J Iqbal; Nicola Mascolo; Vincenzo De Feo
Journal:  Front Pharmacol       Date:  2017-01-06       Impact factor: 5.810

Review 7.  Apolipoprotein E - A Multifunctional Protein with Implications in Various Pathologies as a Result of Its Structural Features.

Authors:  Irina Florina Tudorache; Violeta Georgeta Trusca; Anca Violeta Gafencu
Journal:  Comput Struct Biotechnol J       Date:  2017-06-06       Impact factor: 7.271

8.  COVID-19-Associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches.

Authors:  Alexander V Sorokin; Sotirios K Karathanasis; Zhi-Hong Yang; Lita Freeman; Kazuhiko Kotani; Alan T Remaley
Journal:  FASEB J       Date:  2020-06-26       Impact factor: 5.191

9.  Plasma levels of apolipoprotein-E in residents of the European North of Russia.

Authors:  Anastasiya M Kaneva; Evgeny R Bojko; Natalya N Potolitsyna; Jon O Odland
Journal:  Lipids Health Dis       Date:  2013-03-27       Impact factor: 3.876

10.  Postprandial apoE isoform and conformational changes associated with VLDL lipolysis products modulate monocyte inflammation.

Authors:  Laura J den Hartigh; Robin Altman; Romobia Hutchinson; Jitka Petrlova; Madhu S Budamagunta; Sarada D Tetali; Jens O Lagerstedt; John C Voss; John C Rutledge
Journal:  PLoS One       Date:  2012-11-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.